Regulatory/product note: Separate approved-product evidence, research evidence, and supplier product claims.
Mechanism
Proposed mechanism
Targets GLP-1, GIP, and glucagon receptor pathways involved in appetite, glycemic regulation, and energy/metabolic signaling.
Evidence
Evidence map boundary
This record keeps mechanisms, animal studies, human biomarkers, controlled clinical outcomes, safety data, and supplier documentation separate so claims are not flattened into one misleading score.
Research questions tracked
What exact molecule, route, formulation, and outcome were studied?
Is the evidence mechanistic, animal, early human, or controlled clinical evidence?
Does the commercial product match the studied material and documentation?
Key findings and boundaries
Evidence strength changes by outcome and study type.
Mechanism is useful context but not proof of clinical benefit.
Supplier claims require separate documentation review.
Important gaps
Long-term human safety and real-world product quality are often incomplete.
Claims can exceed the route, formulation, and population studied.
Safety
Safety and unknowns
Safety remains investigational. Trial data should not be transferred to gray-market products sold as Reta or GLP-3.
Known and plausible adverse effects must be separated from product-quality risks.
Injectable or research-use products add sterility, endotoxin, impurity, and handling concerns.
Testing & COAs
Documentation checklist
COAs can support identity, purity, assay, batch traceability, laboratory identity, and testing date review. They do not prove clinical effectiveness, legal status, storage integrity, sterility unless tested, or suitability for use.
Identity, assay/purity, batch matching, lab identity, and test date should be visible.
COAs do not prove clinical effectiveness, legal status, or suitability for use.